{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T03:48:59Z","timestamp":1790480939815,"version":"4.1.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T00:00:00Z","timestamp":1620259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11892-021-01384-6","type":"journal-article","created":{"date-parts":[[2021,5,6]],"date-time":"2021-05-06T11:02:35Z","timestamp":1620298955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Programmed Death-1 in Type 1 Diabetes"],"prefix":"10.1007","volume":"21","author":[{"given":"Christopher G.","family":"Tucker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-5637","authenticated-orcid":false,"given":"Brian T.","family":"Fife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6027-3380","authenticated-orcid":false,"given":"Tijana","family":"Martinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,6]]},"reference":[{"issue":"11","key":"1384_CR1","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395.","journal-title":"EMBO J"},{"issue":"7","key":"1384_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"3","key":"1384_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261\u20138.","journal-title":"Nat Immunol"},{"issue":"7077","key":"1384_CR4","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682\u20137.","journal-title":"Nature."},{"issue":"4","key":"1384_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670\u201384.","journal-title":"Immunity."},{"issue":"2","key":"1384_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, et al. Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis. Immunity. 2016;45(2):389\u2013401.","journal-title":"Immunity."},{"issue":"6","key":"1384_CR7","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Devevre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients. J Clin Invest. 2011;121(6):2350\u201360.","journal-title":"J Clin Invest"},{"issue":"19","key":"1384_CR8","doi-asserted-by":"publisher","first-page":"12293","DOI":"10.1073\/pnas.192461099","volume":"99","author":"Y Iwai","year":"2002","unstructured":"Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1384_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/intimm\/dxh194","volume":"17","author":"Y Iwai","year":"2005","unstructured":"Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol. 2005;17(2):133\u201344.","journal-title":"Int Immunol"},{"issue":"3","key":"1384_CR10","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","volume":"65","author":"F Hirano","year":"2005","unstructured":"Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089\u201396.","journal-title":"Cancer Res"},{"issue":"26","key":"1384_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443\u201354.","journal-title":"N Engl J Med"},{"issue":"26","key":"1384_CR12","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455\u201365.","journal-title":"N Engl J Med"},{"issue":"26","key":"1384_CR13","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"21","key":"1384_CR14","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"1384_CR15","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600\u20139.","journal-title":"JAMA."},{"key":"1384_CR16","doi-asserted-by":"crossref","unstructured":"Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. 2020; 25(5):790\u2013800.","DOI":"10.1007\/s10147-019-01588-7"},{"issue":"6382","key":"1384_CR17","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135.","journal-title":"Science."},{"issue":"1","key":"1384_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1172\/JCI131194","volume":"130","author":"M Dougan","year":"2020","unstructured":"Dougan M, Pietropaolo M. Time to dissect the autoimmune etiology of cancer antibody immunotherapy. J Clin Invest. 2020;130(1):51\u201361.","journal-title":"J Clin Invest"},{"issue":"6","key":"1384_CR19","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR, Lichtman AH, Sharpe AH. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 2019;40(6):511\u201323.","journal-title":"Trends Immunol"},{"key":"1384_CR20","doi-asserted-by":"crossref","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, Clark PL, Kluger H, Weiss SA, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67(8):1471\u201380.","DOI":"10.2337\/dbi18-0002"},{"issue":"2","key":"1384_CR21","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"2","key":"1384_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","volume":"11","author":"H Nishimura","year":"1999","unstructured":"Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141\u201351.","journal-title":"Immunity."},{"issue":"5502","key":"1384_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322.","journal-title":"Science."},{"issue":"4","key":"1384_CR24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883\u201395.","journal-title":"J Exp Med"},{"issue":"1","key":"1384_CR25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity. 2007;27(1):111\u201322.","journal-title":"Immunity."},{"issue":"8","key":"1384_CR26","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.4049\/jimmunol.179.8.5064","volume":"179","author":"ME Keir","year":"2007","unstructured":"Keir ME, Freeman GJ, Sharpe AH. PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol. 2007;179(8):5064\u201370.","journal-title":"J Immunol"},{"issue":"3","key":"1384_CR27","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153\u201367.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"1384_CR28","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1002\/eji.200324228","volume":"33","author":"SC Liang","year":"2003","unstructured":"Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ, et al. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 2003;33(10):2706\u201316.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1384_CR29","doi-asserted-by":"publisher","first-page":"8295","DOI":"10.1038\/s41598-018-26471-9","volume":"8","author":"KC Osum","year":"2018","unstructured":"Osum KC, Burrack AL, Martinov T, Sahli NL, Mitchell JS, Tucker CG, et al. Interferon-gamma drives programmed death-ligand 1 expression on islet beta cells to limit T cell function during autoimmune diabetes. Sci Rep. 2018;8(1):8295.","journal-title":"Sci Rep"},{"issue":"33","key":"1384_CR30","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T. Establishment of NOD-Pdcd1-\/- mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci U S A. 2005;102(33):11823\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1384_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJ Ansari","year":"2003","unstructured":"Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, et al. The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003;198(1):63\u20139.","journal-title":"J Exp Med"},{"issue":"1","key":"1384_CR32","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2007.05.013","volume":"125","author":"I Guleria","year":"2007","unstructured":"Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, et al. Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol. 2007;125(1):16\u201325.","journal-title":"Clin Immunol"},{"issue":"10","key":"1384_CR33","doi-asserted-by":"publisher","first-page":"4913","DOI":"10.4049\/jimmunol.1301927","volume":"191","author":"KE Pauken","year":"2013","unstructured":"Pauken KE, Linehan JL, Spanier JA, Sahli NL, Kalekar LA, Binstadt BA, et al. Cutting edge: type 1 diabetes occurs despite robust anergy among endogenous insulin-specific CD4 T cells in NOD mice. J Immunol. 2013;191(10):4913\u20137.","journal-title":"J Immunol"},{"issue":"9","key":"1384_CR34","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.2337\/db18-0200","volume":"67","author":"RL Baker","year":"2018","unstructured":"Baker RL, Jamison BL, Wiles TA, Lindsay RS, Barbour G, Bradley B, et al. CD4 T cells reactive to hybrid insulin peptides are indicators of disease activity in the NOD mouse. Diabetes. 2018;67(9):1836\u201346.","journal-title":"Diabetes."},{"key":"1384_CR35","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jaut.2016.10.007","volume":"78","author":"TA Wiles","year":"2017","unstructured":"Wiles TA, Delong T, Baker RL, Bradley B, Barbour G, Powell RL, et al. An insulin-IAPP hybrid peptide is an endogenous antigen for CD4 T cells in the non-obese diabetic mouse. J Autoimmun. 2017;78:11\u20138.","journal-title":"J Autoimmun"},{"issue":"8","key":"1384_CR36","doi-asserted-by":"publisher","first-page":"3990","DOI":"10.4049\/jimmunol.1301480","volume":"191","author":"RL Baker","year":"2013","unstructured":"Baker RL, Delong T, Barbour G, Bradley B, Nakayama M, Haskins K. Cutting edge: CD4 T cells reactive to an islet amyloid polypeptide peptide accumulate in the pancreas and contribute to disease pathogenesis in nonobese diabetic mice. J Immunol. 2013;191(8):3990\u20134.","journal-title":"J Immunol"},{"issue":"3","key":"1384_CR37","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.4049\/jimmunol.1003496","volume":"187","author":"AM Paterson","year":"2011","unstructured":"Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, et al. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo. J Immunol. 2011;187(3):1097\u2013105.","journal-title":"J Immunol"},{"issue":"8","key":"1384_CR38","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1158\/2326-6066.CIR-17-0316","volume":"6","author":"A Chaudhri","year":"2018","unstructured":"Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B, Freeman GJ. PD-L1 binds to B7-1 only in cis on the same cell surface. Cancer Immunol Res. 2018;6(8):921\u20139.","journal-title":"Cancer Immunol Res"},{"issue":"6440","key":"1384_CR39","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1126\/science.aav7062","volume":"364","author":"D Sugiura","year":"2019","unstructured":"Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1\/CD80 interactions is required for optimal T cell responses. Science. 2019;364(6440):558\u201366.","journal-title":"Science."},{"issue":"6","key":"1384_CR40","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.immuni.2019.11.003","volume":"51","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Lee CK, Lin CH, Gassen RB, Xu X, Huang Z, et al. PD-L1:CD80 Cis-heterodimer triggers the co-stimulatory receptor CD28 while repressing the inhibitory PD-1 and CTLA-4 pathways. Immunity. 2019;51(6):1059\u201373 e9.","journal-title":"Immunity."},{"key":"1384_CR41","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ebiom.2018.09.040","volume":"36","author":"ML Colli","year":"2018","unstructured":"Colli ML, Hill JLE, Marroqui L, Chaffey J, Dos Santos RS, Leete P, et al. PDL1 is expressed in the islets of people with type 1 diabetes and is up-regulated by interferons-alpha and-gamma via IRF1 induction. EBioMedicine. 2018;36:367\u201375.","journal-title":"EBioMedicine."},{"issue":"1","key":"1384_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.celrep.2018.03.026","volume":"23","author":"G Rota","year":"2018","unstructured":"Rota G, Niogret C, Dang AT, Barros CR, Fonta NP, Alfei F, et al. Shp-2 Is Dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo. Cell Rep. 2018;23(1):39\u201349.","journal-title":"Cell Rep"},{"issue":"6","key":"1384_CR43","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209(6):1201\u201317.","journal-title":"J Exp Med"},{"issue":"6332","key":"1384_CR44","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui E, Cheung J, Zhu J, Su X, Taylor MJ, Wallweber HA, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428\u201333.","journal-title":"Science."},{"issue":"6332","key":"1384_CR45","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science. 2017;355(6332):1423\u20137.","journal-title":"Science."},{"issue":"11","key":"1384_CR46","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/ni.1790","volume":"10","author":"BT Fife","year":"2009","unstructured":"Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol. 2009;10(11):1185\u201392.","journal-title":"Nat Immunol"},{"issue":"13","key":"1384_CR47","doi-asserted-by":"publisher","first-page":"107827","DOI":"10.1016\/j.celrep.2020.107827","volume":"31","author":"KE Pauken","year":"2020","unstructured":"Pauken KE, Godec J, Odorizzi PM, Brown KE, Yates KB, Ngiow SF, et al. The PD-1 pathway regulates development and function of memory CD8(+) T cells following respiratory viral infection. Cell Rep. 2020;31(13):107827.","journal-title":"Cell Rep"},{"issue":"12","key":"1384_CR48","doi-asserted-by":"publisher","first-page":"8291","DOI":"10.4049\/jimmunol.177.12.8291","volume":"177","author":"N Martin-Orozco","year":"2006","unstructured":"Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: programmed death (PD) ligand-1\/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol. 2006;177(12):8291\u20135.","journal-title":"J Immunol"},{"key":"1384_CR49","doi-asserted-by":"publisher","first-page":"102296","DOI":"10.1016\/j.jaut.2019.06.007","volume":"105","author":"H Okamura","year":"2019","unstructured":"Okamura H, Okazaki IM, Shimizu K, Maruhashi T, Sugiura D, Mizuno R, et al. PD-1 aborts the activation trajectory of autoreactive CD8(+) T cells to prohibit their acquisition of effector functions. J Autoimmun. 2019;105:102296.","journal-title":"J Autoimmun"},{"issue":"6","key":"1384_CR50","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.2353\/ajpath.2006.060539","volume":"169","author":"B Calderon","year":"2006","unstructured":"Calderon B, Suri A, Unanue ER. In CD4+ T-cell-induced diabetes, macrophages are the final effector cells that mediate islet beta-cell killing: studies from an acute model. Am J Pathol. 2006;169(6):2137\u201347.","journal-title":"Am J Pathol"},{"issue":"7","key":"1384_CR51","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.4049\/jimmunol.166.7.4481","volume":"166","author":"K Suk","year":"2001","unstructured":"Suk K, Kim S, Kim YH, Kim KA, Chang I, Yagita H, et al. IFN-gamma\/TNF-alpha synergism as the final effector in autoimmune diabetes: a key role for STAT1\/IFN regulatory factor-1 pathway in pancreatic beta cell death. J Immunol. 2001;166(7):4481\u20139.","journal-title":"J Immunol"},{"issue":"4","key":"1384_CR52","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"S Crotty","year":"2014","unstructured":"Crotty S. T follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41(4):529\u201342.","journal-title":"Immunity."},{"issue":"6","key":"1384_CR53","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1084\/jem.20151869","volume":"213","author":"X Wan","year":"2016","unstructured":"Wan X, Thomas JW, Unanue ER. Class-switched anti-insulin antibodies originate from unconventional antigen presentation in multiple lymphoid sites. J Exp Med. 2016;213(6):967\u201378.","journal-title":"J Exp Med"},{"issue":"8","key":"1384_CR54","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.4049\/jimmunol.171.8.4040","volume":"171","author":"S Gregori","year":"2003","unstructured":"Gregori S, Giarratana N, Smiroldo S, Adorini L. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development. J Immunol. 2003;171(8):4040\u20137.","journal-title":"J Immunol"},{"issue":"5","key":"1384_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.immuni.2008.03.016","volume":"28","author":"Q Tang","year":"2008","unstructured":"Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28(5):687\u201397.","journal-title":"Immunity."},{"key":"1384_CR56","doi-asserted-by":"crossref","unstructured":"Martinov T, Fife BT. Type 1 diabetes pathogenesis and the role of inhibitory receptors in islet tolerance. Ann N Y Acad Sci. 2019;1461(1):73\u2013103.","DOI":"10.1111\/nyas.14106"},{"issue":"2","key":"1384_CR57","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/ni.2496","volume":"14","author":"PT Sage","year":"2013","unstructured":"Sage PT, Francisco LM, Carman CV, Sharpe AH. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol. 2013;14(2):152\u201361.","journal-title":"Nat Immunol"},{"issue":"8","key":"1384_CR58","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.4049\/jimmunol.1701231","volume":"200","author":"PT Sage","year":"2018","unstructured":"Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, Sharpe AH. Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function. J Immunol. 2018;200(8):2592\u2013602.","journal-title":"J Immunol"},{"issue":"10","key":"1384_CR59","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1084\/jem.20051409","volume":"202","author":"Z Chen","year":"2005","unstructured":"Chen Z, Herman AE, Matos M, Mathis D, Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes. J Exp Med. 2005;202(10):1387\u201397.","journal-title":"J Exp Med"},{"issue":"8","key":"1384_CR60","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.2337\/db12-1475","volume":"62","author":"KE Pauken","year":"2013","unstructured":"Pauken KE, Jenkins MK, Azuma M, Fife BT. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes. Diabetes. 2013;62(8):2859\u201369.","journal-title":"Diabetes."},{"issue":"8","key":"1384_CR61","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.4049\/jimmunol.1402262","volume":"194","author":"KE Pauken","year":"2015","unstructured":"Pauken KE, Nelson CE, Martinov T, Spanier JA, Heffernan JR, Sahli NL, et al. Cutting edge: identification of autoreactive CD4+ and CD8+ T cell subsets resistant to PD-1 pathway blockade. J Immunol. 2015;194(8):3551\u20135.","journal-title":"J Immunol"},{"issue":"4","key":"1384_CR62","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","volume":"21","author":"B Diskin","year":"2020","unstructured":"Diskin B, Adam S, Cassini MF, Sanchez G, Liria M, Aykut B, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. Nat Immunol. 2020;21(4):442\u201354.","journal-title":"Nat Immunol"},{"issue":"3","key":"1384_CR63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1172\/JCI16015","volume":"111","author":"H Dong","year":"2003","unstructured":"Dong H, Strome SE, Matteson EL, Moder KG, Flies DB, Zhu G, et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J Clin Invest. 2003;111(3):363\u201370.","journal-title":"J Clin Invest"},{"issue":"7039","key":"1384_CR64","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nature03523","volume":"435","author":"M Nakayama","year":"2005","unstructured":"Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005;435(7039):220\u20133.","journal-title":"Nature."},{"issue":"7","key":"1384_CR65","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.celrep.2016.10.042","volume":"17","author":"TT Jiang","year":"2016","unstructured":"Jiang TT, Martinov T, Xin L, Kinder JM, Spanier JA, Fife BT, et al. Programmed death-1 culls peripheral accumulation of high-affinity autoreactive CD4 T cells to protect against autoimmunity. Cell Rep. 2016;17(7):1783\u201394.","journal-title":"Cell Rep"},{"issue":"4","key":"1384_CR66","doi-asserted-by":"publisher","first-page":"844","DOI":"10.4049\/jimmunol.1801535","volume":"203","author":"T Martinov","year":"2019","unstructured":"Martinov T, Swanson LA, Breed ER, Tucker CG, Dwyer AJ, Johnson JK, et al. Programmed death-1 restrains the germinal center in type 1 diabetes. J Immunol. 2019;203(4):844\u201352.","journal-title":"J Immunol"},{"issue":"20","key":"1384_CR67","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, et al. PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116(20):9999\u201310008.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1384_CR68","doi-asserted-by":"crossref","unstructured":"Tan CL, Kuchroo JR, Sage PT, Liang D, Francisco LM, Buck J, et al. PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021;218(1):e20182232.","DOI":"10.1084\/jem.20182232"},{"issue":"1","key":"1384_CR69","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1038\/s41598-018-38432-3","volume":"9","author":"K Neumann","year":"2019","unstructured":"Neumann K, Ostmann A, Breda PC, Ochel A, Tacke F, Paust HJ, et al. The co-inhibitory molecule PD-L1 contributes to regulatory T cell-mediated protection in murine crescentic glomerulonephritis. Sci Rep. 2019;9(1):2038.","journal-title":"Sci Rep"},{"issue":"6411","key":"1384_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.aau2688","volume":"362","author":"JA Bluestone","year":"2018","unstructured":"Bluestone JA, Tang Q. Treg cells-the next frontier of cell therapy. Science. 2018;362(6411):154\u20135.","journal-title":"Science."},{"issue":"10","key":"1384_CR71","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1093\/intimm\/10.10.1563","volume":"10","author":"H Nishimura","year":"1998","unstructured":"Nishimura H, Minato N, Nakano T, Honjo T. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int Immunol. 1998;10(10):1563\u201372.","journal-title":"Int Immunol"},{"issue":"7655","key":"1384_CR72","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature."},{"issue":"43","key":"1384_CR73","doi-asserted-by":"publisher","first-page":"eaay1863","DOI":"10.1126\/sciimmunol.aay1863","volume":"5","author":"L Strauss","year":"2020","unstructured":"Strauss L, Mahmoud MAA, Weaver JD, Tijaro-Ovalle NM, Christofides A, Wang Q, et al. Targeted deletion of PD-1 in myeloid cells induces antitumor immunity. Sci Immunol. 2020;5(43):eaay1863.","journal-title":"Sci Immunol"},{"issue":"1","key":"1384_CR74","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41598-020-57507-8","volume":"10","author":"Z Parackova","year":"2020","unstructured":"Parackova Z, Vrabcova P, Zentsova I, Kayserova J, Richtrova I, Sojka L, et al. Enhanced STAT3 phosphorylation and PD-L1 expression in myeloid dendritic cells indicate impaired IL-27Ralpha signaling in type 1 diabetes. Sci Rep. 2020;10(1):493.","journal-title":"Sci Rep"},{"issue":"1","key":"1384_CR75","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.transproceed.2014.10.043","volume":"47","author":"T Li","year":"2015","unstructured":"Li T, Ma R, Zhu JY, Wang FS, Huang L, Leng XS. PD-1\/PD-L1 costimulatory pathway-induced mouse islet transplantation immune tolerance. Transplant Proc. 2015;47(1):165\u201370.","journal-title":"Transplant Proc"},{"issue":"2","key":"1384_CR76","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2337\/db13-1737","volume":"64","author":"R Li","year":"2015","unstructured":"Li R, Lee J, Kim MS, Liu V, Moulik M, Li H, et al. PD-L1-driven tolerance protects neurogenin3-induced islet neogenesis to reverse established type 1 diabetes in NOD mice. Diabetes. 2015;64(2):529\u201340.","journal-title":"Diabetes."},{"issue":"5","key":"1384_CR77","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gt.2015.18","volume":"22","author":"MM El Khatib","year":"2015","unstructured":"El Khatib MM, Sakuma T, Tonne JM, Mohamed MS, Holditch SJ, Lu B, et al. Beta-cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection. Gene Ther. 2015;22(5):430\u20138.","journal-title":"Gene Ther"},{"issue":"5","key":"1384_CR78","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1172\/JCI19210","volume":"113","author":"SK Subudhi","year":"2004","unstructured":"Subudhi SK, Zhou P, Yerian LM, Chin RK, Lo JC, Anders RA, et al. Local expression of B7-H1 promotes organ-specific autoimmunity and transplant rejection. J Clin Invest. 2004;113(5):694\u2013700.","journal-title":"J Clin Invest"},{"issue":"26","key":"1384_CR79","doi-asserted-by":"publisher","first-page":"e1907692","DOI":"10.1002\/adma.201907692","volume":"32","author":"X Zhang","year":"2020","unstructured":"Zhang X, Kang Y, Wang J, Yan J, Chen Q, Cheng H, et al. Engineered PD-L1-expressing platelets reverse new-onset type 1 diabetes. Adv Mater. 2020;32(26):e1907692.","journal-title":"Adv Mater"},{"issue":"6","key":"1384_CR80","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1046\/j.1399-0039.2003.00136.x","volume":"62","author":"C Nielsen","year":"2003","unstructured":"Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens. 2003;62(6):492\u20137.","journal-title":"Tissue Antigens"},{"issue":"8","key":"1384_CR81","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/dmrr.2552","volume":"30","author":"C Pizarro","year":"2014","unstructured":"Pizarro C, Garcia-Diaz DF, Codner E, Salas-Perez F, Carrasco E, Perez-Bravo F. PD-L1 gene polymorphisms and low serum level of PD-L1 protein are associated to type 1 diabetes in Chile. Diabetes Metab Res Rev. 2014;30(8):761\u20136.","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"1384_CR82","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00439-006-0309-8","volume":"121","author":"R Ni","year":"2007","unstructured":"Ni R, Ihara K, Miyako K, Kuromaru R, Inuo M, Kohno H, et al. PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. Hum Genet. 2007;121(2):223\u201332.","journal-title":"Hum Genet"},{"key":"1384_CR83","doi-asserted-by":"publisher","first-page":"1614683","DOI":"10.1155\/2018\/1614683","volume":"2018","author":"C Qian","year":"2018","unstructured":"Qian C, Guo H, Chen X, Shi A, Li S, Wang X, et al. Association of PD-1 and PD-L1 genetic polymorphyisms with type 1 diabetes susceptibility. J Diabetes Res. 2018;2018:1614683.","journal-title":"J Diabetes Res"},{"issue":"12","key":"1384_CR84","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1111\/j.1464-5491.2007.02297.x","volume":"24","author":"S Asad","year":"2007","unstructured":"Asad S, Nikamo P, Torn C, Landin-Olsson M, Lernmark A, Alarcon-Riquelme M, et al. No evidence of association of the PDCD1 gene with type 1 diabetes. Diabet Med. 2007;24(12):1473\u20137.","journal-title":"Diabet Med"},{"issue":"5","key":"1384_CR85","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1744-313X.2010.00935.x","volume":"37","author":"M Fichna","year":"2010","unstructured":"Fichna M, Zurawek M, Januszkiewicz-Lewandowska D, Fichna P, Nowak J. PTPN22, PDCD1 and CYP27B1 polymorphisms and susceptibility to type 1 diabetes in Polish patients. Int J Immunogenet. 2010;37(5):367\u201372.","journal-title":"Int J Immunogenet"},{"issue":"28","key":"1384_CR86","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.18632\/oncotarget.27665","volume":"11","author":"K Yun","year":"2020","unstructured":"Yun K, Daniels G, Gold K, McCowen K, Patel SP. Rapid onset type 1 diabetes with anti-PD-1 directed therapy. Oncotarget. 2020;11(28):2740\u20136.","journal-title":"Oncotarget."},{"key":"1384_CR87","doi-asserted-by":"crossref","unstructured":"Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J. New onset diabetes with ketoacidosis following nivolumab immunotherapy: a case report and review of literature. J Oncol Pharm Pract. 2021;27(3):716\u201321.","DOI":"10.1177\/1078155220943949"},{"issue":"1","key":"1384_CR88","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41572-020-0165-1","volume":"6","author":"KK Dhatariya","year":"2020","unstructured":"Dhatariya KK, Glaser NS, Codner E, Umpierrez GE. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020;6(1):40.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1384_CR89","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1172\/JCI96798","volume":"128","author":"R Das","year":"2018","unstructured":"Das R, Bar N, Ferreira M, Newman AM, Zhang L, Bailur JK, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest. 2018;128(2):715\u201320.","journal-title":"J Clin Invest"},{"issue":"3","key":"1384_CR90","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaoncol.2018.5860","volume":"5","author":"Y Toi","year":"2019","unstructured":"Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2019;5(3):376\u201383.","journal-title":"JAMA Oncol"},{"issue":"44","key":"1384_CR91","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019;116(44):22246\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1384_CR92","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2337\/dc07-1459","volume":"31","author":"JM Sosenko","year":"2008","unstructured":"Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, et al. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care. 2008;31(3):528\u201333.","journal-title":"Diabetes Care"},{"issue":"3","key":"1384_CR93","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2337\/dc15-1111","volume":"39","author":"RA Oram","year":"2016","unstructured":"Oram RA, Patel K, Hill A, Shields B, McDonald TJ, Jones A, et al. A type 1 diabetes genetic risk score can aid discrimination between type 1 and type 2 diabetes in young adults. Diabetes Care. 2016;39(3):337\u201344.","journal-title":"Diabetes Care"},{"issue":"9","key":"1384_CR94","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2337\/dc18-0087","volume":"41","author":"MJ Redondo","year":"2018","unstructured":"Redondo MJ, Geyer S, Steck AK, Sharp S, Wentworth JM, Weedon MN, et al. A type 1 diabetes genetic risk score predicts progression of islet autoimmunity and development of type 1 diabetes in individuals at risk. Diabetes Care. 2018;41(9):1887\u201394.","journal-title":"Diabetes Care"},{"issue":"2","key":"1384_CR95","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S, Atkinson VG, Wong ANM, Park JJ, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28(2):368\u201376.","journal-title":"Ann Oncol"},{"key":"1384_CR96","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejca.2016.12.038","volume":"75","author":"R Gutzmer","year":"2017","unstructured":"Gutzmer R, Koop A, Meier F, Hassel JC, Terheyden P, Zimmer L, et al. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity. Eur J Cancer. 2017;75:24\u201332.","journal-title":"Eur J Cancer"},{"key":"1384_CR97","doi-asserted-by":"crossref","unstructured":"Lai HC, Lin JF, Hwang TIS, Liu YF, Yang AH, Wu CK. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? Int J Mol Sci. 2019;20(9).","DOI":"10.3390\/ijms20092194"},{"issue":"5","key":"1384_CR98","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1172\/JCI97739","volume":"128","author":"DA Ostrov","year":"2018","unstructured":"Ostrov DA, Alkanani A, McDaniel KA, Case S, Baschal EE, Pyle L, et al. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest. 2018;128(5):1888\u2013902.","journal-title":"J Clin Invest"},{"issue":"12","key":"1384_CR99","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1084\/jem.20061577","volume":"203","author":"BT Fife","year":"2006","unstructured":"Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, et al. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J Exp Med. 2006;203(12):2737\u201347.","journal-title":"J Exp Med"},{"key":"1384_CR100","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","volume":"103","author":"M Tenspolde","year":"2019","unstructured":"Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J, et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun. 2019;103:102289.","journal-title":"J Autoimmun"},{"issue":"11","key":"1384_CR101","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1084\/jem.20040139","volume":"199","author":"Q Tang","year":"2004","unstructured":"Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199(11):1455\u201365.","journal-title":"J Exp Med"},{"key":"1384_CR102","doi-asserted-by":"crossref","unstructured":"Yu JX, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM, Tang J. Trends in clinical development for PD-1\/PD-L1 inhibitors. Nat Rev Drug Discov. 2020;19(3):163\u201364.","DOI":"10.1038\/d41573-019-00182-w"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-021-01384-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-021-01384-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-021-01384-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T22:29:42Z","timestamp":1666909782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-021-01384-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,6]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1384"],"URL":"https:\/\/doi.org\/10.1007\/s11892-021-01384-6","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,6]]},"assertion":[{"value":"24 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christopher G. Tucker, Alexander J. Dwyer, and Tijana Martinov each declare no potential conflicts of interest.Brian T. Fife has a patent pending for Monoclonal antibodies directed to peptide in the context of MHC and methods of making and using monoclonal antibodies; Office: United States of America. Application number: 15952965; application date: 13.04.2018; publication number: 20180298103; publication date: 18.10.2018.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"20"}}